Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer

British Journal of Cancer

Volumn 90, Issue 9, 2004, Pages 1740-1746

  Batista, N ^a   Perez Manga, G ^b   Constenla, M ^c   Ruiz, A ^d   Carabantes, F ^e   Castellanos, J ^f   Gonzalez Baron M ^g   Villman, K ^h   Soderberg M ⁱ   Ahlgren, J ^j   Casinello, J ^k   Regueiro, P ^l   Murias, A ^m  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL MONTECELO   (Spain)

^d IVO   (Spain)

^e HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^f HOSPITAL XERAL CÍES   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

ⁱ Central Hospital of Karlstad   (Sweden)

^j UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^k HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^l F Hoffmann La Roche   (Spain)

^m HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

more..

Author keywords

Anthracycline; Breast cancer; Capecitabine; Fluoropyrimidines; Oral; Paclitaxel

Indexed keywords

ANTHRACYCLINE; ANTIHISTAMINIC AGENT; CAPECITABINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOCETAXEL; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; PACLITAXEL;

ADULT; AGED; ALOPECIA; ARTICLE; ASCITES; ASTHENIA; BREAST CANCER; BRONCHOSPASM; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERSENSITIVITY; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PREDICTION; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TOXICITY; VOMITING;

EID: 2642544907     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601784     Document Type: Article

References (31)

1. Abrams JS, Vena DA, Baltz J, Adams J, Montello M, Christian M, Onetto N, Desmond-Hellmann S, Canetta R, Friedman MA, Arbuck SG (1995) Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J Clin Oncol 13: 2056-2065
2. Blum JL (2001) The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 6: 56-64
3. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B (2001a) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92: 1759-1768
4. Blum JL, Jones SE, Buzdar AU (2001b) Capecitabine in 162 patients with paclitaxel-pretreated MBC: updated results and analysis of dose-modification. Eur J Cancer 37(Suppl 6): 190 (abstr. 693)
5. Blum JL, Jones SE, Buzdar AU, Lo Russo PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485-493
6. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendrick J, Maroun J, Marshall J, Osterwalder B, Pérez-Managa G, Rosso R, Rougier P, Schilsky RL (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13: 566-575
7. Dieras V, Marty M, Tubiana N, Corette L, Morvan F, Serin D, Mignot L, Chazard M, Garet F, Onetto N, Hellmann S, Pouillart P (1995) Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer. Semin Oncol 22: 33-39
8. Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143-151
9. Fountzilas G, Athanassiades A, Giannakakis T, Bafaloukos D, Karakousis K, Dombros N, Kosmidis P, Skarlos D (1996) A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 32: 47-51
10. Fumoleau P, Largillier R, Clippe C, Dièras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Curé H, Vuillemin E, Morère J-F, Montestruc F, Mouri Z, Namer M (2004) Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40: 536-542
11. Gianni L, Munzone E, Capri G, Villani F, Spreafico C, Tarenzi E, Fulfaro F, Caraceni A, Martini C, Laffranchi A (1995) Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87: 1169-1175
12. Gradishar W, Meza L, Hill T, Samid D, Chen Y-M, Amin B (2003) A multicenter phase II study of capecitabine plus paclitaxel in metastatic breast cancer: survival update. Eur J Cancer 1(Suppl. 5): S141 (abstr. 463)
13. Holmes FA, Valero V, Buzdar AU, Booser DJ, Winn R, Tolcher A, Seidman A, Goodwin W, Bearden J, Baysinger L, Hortobagyi GN, Arbuck SA (1998) Final results: randomized phase II trial of paclitaxel by 3-hr versus 96-hr infusion in patients (pt) with met breast cancer (MBC). The long & short of it. Proc Am Soc Clin Oncol 17: 110a (abstr. 426)
14. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805
15. Ishitsuka H (2000) Capecitabine: preclinical pharmacology studies. Invest New Drugs 18: 343-354
16. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281
17. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B (1996) Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858-1867
18. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline- containing chemotherapy. 304 Study Group. J Clin Oncol 17: 1413-1424
19. O'Shaughnessy JA, Nag S, Calderillo-Ruiz G, Jordaan J, Llombart A, Pluzanska A, Pawlicki M, Reyes JM, Sekhon J, Albain KS (2003) Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study. Proc Am Soc Clin Oncol 22: 7 (abstr. 25)
20. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823
21. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with crossover. J Clin Oncol 18: 724-733
22. Reichardt P, von Minckwitz G, Thuss-Patience PC, Jonat W, Kölbl H, Jänicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M, Lück HJ (2003) Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer, relapsing after treatment with a taxane-containing therapy. Ann Oncol 14: 1227-1233
23. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019
24. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45: 291-297
25. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16: 3353-3361
26. Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P (1995a) Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13: 1152-1159
27. Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V, Crown J (1995b) Phase II trial of paclitaxel by 3-hour infusion as initial and salvage therapy for metastatic breast cancer. J Clin Oncol 13: 2575-2581
28. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC (2003) Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21: 588-592
29. Smith RE, Brown AM, Mamounas EP, Anderson SJ, Lembersky BC, Atkins JH, Shibata HR, Baez L, DeFusco PA, Davila E, Tipping SJ, Bearden JD, Thirlwell MP (1999) Randomized trial of 3-hour versus 24-hour infusion of high dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 17: 3403-3411
30. Villalona-Calero MA, Blum JL, Jones SE, Diab S, Elledge R, Khoury P, Von Hoff D, Kraynak M, Moczygemba J, Kromelis P, Griffin T, Rowinsky EK (2001) A phase I and pharmacokinetic study of capecitabine and paclitaxel in breast cancer patients. Ann Oncol 12: 605-614
31. WHO Handbook for Reporting Results of Cancer Treatment (1979) WHO Offset Publication No. 48. World Health Organization, Geneva